Literature DB >> 20026761

Inching towards a targeted therapy for preeclampsia.

Ravi Thadhani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20026761      PMCID： PMC4040955          DOI： 10.1161/HYPERTENSIONAHA.109.143933

Source DB:  PubMed          Journal:  Hypertension        ISSN： 0194-911X            Impact factor:   10.190


× No keyword cloud information.
  9 in total

1.  Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases.

Authors:  Marc Feldmann; Ravinder N Maini
Journal:  Nat Med       Date:  2003-10       Impact factor: 53.440

Review 2.  Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction.

Authors:  Jeffrey S Gilbert; Michael J Ryan; Babbette B LaMarca; Mona Sedeek; Sydney R Murphy; Joey P Granger
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-11-30       Impact factor: 4.733

3.  Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1.

Authors:  A Makris; C Thornton; J Thompson; S Thomson; R Martin; R Ogle; R Waugh; P McKenzie; P Kirwan; A Hennessy
Journal:  Kidney Int       Date:  2007-03-21       Impact factor: 10.612

4.  Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension.

Authors:  Jeffrey S Gilbert; Joseph Verzwyvelt; Drew Colson; Marietta Arany; S Ananth Karumanchi; Joey P Granger
Journal:  Hypertension       Date:  2009-12-21       Impact factor: 10.190

5.  Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.

Authors:  Sharon E Maynard; Jiang-Yong Min; Jaime Merchan; Kee-Hak Lim; Jianyi Li; Susanta Mondal; Towia A Libermann; James P Morgan; Frank W Sellke; Isaac E Stillman; Franklin H Epstein; Vikas P Sukhatme; S Ananth Karumanchi
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

6.  Circulating angiogenic factors and the risk of preeclampsia.

Authors:  Richard J Levine; Sharon E Maynard; Cong Qian; Kee-Hak Lim; Lucinda J England; Kai F Yu; Enrique F Schisterman; Ravi Thadhani; Benjamin P Sachs; Franklin H Epstein; Baha M Sibai; Vikas P Sukhatme; S Ananth Karumanchi
Journal:  N Engl J Med       Date:  2004-02-05       Impact factor: 91.245

7.  Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia.

Authors:  Zhihe Li; Ying Zhang; Jing Ying Ma; Ann M Kapoun; Qiming Shao; Irene Kerr; Andrew Lam; Gilbert O'Young; Frederick Sannajust; Peter Stathis; George Schreiner; S Ananth Karumanchi; Andrew A Protter; N Stephen Pollitt
Journal:  Hypertension       Date:  2007-08-27       Impact factor: 10.190

Review 8.  Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia--a step forward but not the definitive answer.

Authors:  J M Foidart; J P Schaaps; F Chantraine; C Munaut; S Lorquet
Journal:  J Reprod Immunol       Date:  2009-10-23       Impact factor: 4.054

Review 9.  Pregnancy and the kidney.

Authors:  Sharon E Maynard; Ravi Thadhani
Journal:  J Am Soc Nephrol       Date:  2008-12-31       Impact factor: 10.121
  9 in total
  6 in total

Review 1.  A Review of Angiogenic Imbalance in HIV-Infected Hypertensive Disorders of Pregnancy.

Authors:  Sayuri Padayachee; Jagidesa Moodley; Thajasvarie Naicker
Journal:  Curr Hypertens Rep       Date:  2019-07-24       Impact factor: 5.369

2.  Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia.

Authors:  Ravi Thadhani; Henning Hagmann; Wiebke Schaarschmidt; Bernhard Roth; Tuelay Cingoez; S Ananth Karumanchi; Julia Wenger; Kathryn J Lucchesi; Hector Tamez; Tom Lindner; Alexander Fridman; Ulrich Thome; Angela Kribs; Marco Danner; Stefanie Hamacher; Peter Mallmann; Holger Stepan; Thomas Benzing
Journal:  J Am Soc Nephrol       Date:  2015-09-24       Impact factor: 10.121

3.  Protective Low-Frequency Variants for Preeclampsia in the Fms Related Tyrosine Kinase 1 Gene in the Finnish Population.

Authors:  A Inkeri Lokki; Emma Daly; Michael Triebwasser; Mitja I Kurki; Elisha D O Roberson; Paavo Häppölä; Kirsi Auro; Markus Perola; Seppo Heinonen; Eero Kajantie; Juha Kere; Katja Kivinen; Anneli Pouta; Jane E Salmon; Seppo Meri; Mark Daly; John P Atkinson; Hannele Laivuori
Journal:  Hypertension       Date:  2017-06-26       Impact factor: 10.190

4.  Bothrops jararaca peptide with anti-hypertensive action normalizes endothelium dysfunction involved in physiopathology of preeclampsia.

Authors:  Gabriel Benedetti; Katia L P Morais; Juliano R Guerreiro; Eduardo Fontana de Oliveira; Mara Sandra Hoshida; Leandro Oliveira; Nelson Sass; Ivo Lebrun; Henning Ulrich; Claudiana Lameu; Antonio Carlos Martins de Camargo
Journal:  PLoS One       Date:  2011-08-17       Impact factor: 3.240

Review 5.  Personalized Therapy Against Preeclampsia by Replenishing Placental Protein 13 (PP13) Targeted to Patients With Impaired PP13 Molecule or Function.

Authors:  Hamutal Meiri; George Osol; Irene Cetin; Sveinbjörn Gizurarson; Berthold Huppertz
Journal:  Comput Struct Biotechnol J       Date:  2017-09-22       Impact factor: 7.271

Review 6.  Imbalances in circulating angiogenic factors in the pathophysiology of preeclampsia and related disorders.

Authors:  Sarosh Rana; Suzanne D Burke; S Ananth Karumanchi
Journal:  Am J Obstet Gynecol       Date:  2020-10-20       Impact factor: 8.661
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.